Health Blueprint

Back to Longevity News

News summary

Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum

Source: BioSpace - Funding • Published: 02 Nov 2026, 01:18

Summarized by Masters of Longevity from BioSpace - Funding.

Company received a $1.5M installment advancing preclinical DARE-LARC1 work.

Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum
Key Takeaways
  • Daré has received $43.3M in grant funding to date.
  • The $1.5M installment supports nonclinical work toward an IND.
  • DARE-IDDS is investigational and its human efficacy remains unproven.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.